Breast cancer, early stage
Individual patient data Meta-Analysis of 5 Non-Inferiority RCTs of Reduced Duration single agent adjuvant Trastuzumab in the treatment of HER2 positive Early Breast Cancer
H.M. Earl, et al.
Six months trastuzumab is non-inferior to 12months, although nine weeks is not.
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomised trials
V. Guarneri, et al.
These findings further validate the role of pCR as a strong predictor of outcome in patients with HER2+, especially in hormone receptor-negative disease. Moreover, we here provide robust evidence that dual blockade with L in combination with T and chemotherapy prolongs overall survival, suggesting that L could be repurposed in early settings.
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a randomised, phase 3 trial of the Gruppo Italiano Mammella.
L. Del Mastro, et al.
In post-menopausal breast cancer patients treated with 2-3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in a significant and clinically meaningful improvement in both DFS and OS compared to the duration of 2-3 years of letrozole.
Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after _4 years of follow-up: BrighTNess, a randomized Phase 3 trial
S. Loibl, et al.
Adding Cb to P improved pCR and EFS without increasing MDS or acute myeloid leukemia. Addition of V did not impact pCR or EFS. Mortality rate was low, but numerically higher with P than PCbV and PCb.